Capricor Therapeutics (NASDAQ: CAPR) announced the presentation of data from its Phase 3 HOPE-3 clinical trial of Deramiocel for Duchenne ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE